메뉴 건너뛰기




Volumn 20, Issue 9, 2014, Pages 1668-1677

Fecal biomarkers in the diagnosis and monitoring of Crohn's disease

Author keywords

Calprotectin; Crohn's disease; Fecal biomarkers; Inflammatory bowel disease; Lactoferrin; Postoperative; S100A12; Stool tests

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN; LACTOFERRIN; S100A12 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

EID: 84922418194     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000087     Document Type: Review
Times cited : (41)

References (110)
  • 1
    • 54049153170 scopus 로고    scopus 로고
    • Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings
    • Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
    • (2008) Aliment Pharmacol Ther. , vol.28 , pp. 1221-1229
    • Sipponen, T.1    Karkkainen, P.2    Savilahti, E.3
  • 2
    • 0024407591 scopus 로고
    • Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?
    • Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 1989;30:1236-1240.
    • (1989) Gut. , vol.30 , pp. 1236-1240
    • Crama-Bohbouth, G.1    Pena, A.S.2    Biemond, I.3
  • 3
    • 0017227303 scopus 로고
    • Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
    • Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
    • (1976) Gastroenterology , vol.70 , pp. 439-444
    • Best, W.R.1    Becktel, J.M.2    Singleton, J.W.3
  • 4
    • 84862524860 scopus 로고    scopus 로고
    • Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    • D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
    • (2012) Inflamm Bowel Dis. , vol.18 , pp. 2218-2224
    • D'Haens, G.1    Ferrante, M.2    Vermeire, S.3
  • 5
    • 55149092209 scopus 로고    scopus 로고
    • Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
    • Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
    • (2008) Clin Gastroenterol Hepatol. , vol.6 , pp. 1218-1224
    • Jones, J.1    Loftus, E.V.2    Panaccione, R.3
  • 6
    • 38849204268 scopus 로고    scopus 로고
    • Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings
    • Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 40-46
    • Sipponen, T.1    Savilahti, E.2    Kolho, K.L.3
  • 7
    • 24644474678 scopus 로고    scopus 로고
    • Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
    • Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
    • (2005) Inflamm Bowel Dis. , vol.11 , pp. 707-712
    • Solem, C.A.1    Loftus, E.V.2    Tremaine, W.J.3
  • 8
    • 0023713590 scopus 로고
    • The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study
    • Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405.
    • (1988) J Clin Gastroenterol , vol.10 , pp. 401-405
    • Boirivant, M.1    Leoni, M.2    Tariciotti, D.3
  • 9
    • 0026744132 scopus 로고
    • Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study
    • Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
    • (1992) Scand J Gastroenterol , vol.27 , pp. 793-798
    • Roseth, A.G.1    Fagerhol, M.K.2    Aadland, E.3
  • 11
    • 57449085396 scopus 로고    scopus 로고
    • Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease
    • Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66.
    • (2009) Dig Liver Dis. , vol.41 , pp. 56-66
    • Gisbert, J.P.1    McNicholl, A.G.2
  • 12
    • 70350653920 scopus 로고    scopus 로고
    • Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease
    • Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746-1754.
    • (2009) Inflamm Bowel Dis. , vol.15 , pp. 1746-1754
    • Gisbert, J.P.1    McNicholl, A.G.2    Gomollon, F.3
  • 13
    • 34248167206 scopus 로고    scopus 로고
    • Enzymes in feces: Useful markers of chronic inflammatory bowel disease
    • Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
    • (2007) Clin Chim Acta. , vol.381 , pp. 63-68
    • Angriman, I.1    Scarpa, M.2    D'Incà, R.3
  • 14
    • 0036113795 scopus 로고    scopus 로고
    • Review article: Faecal markers in the assessment of activity in inflammatory bowel disease
    • Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-681.
    • (2002) Aliment Pharmacol Ther. , vol.16 , pp. 675-681
    • Poullis, A.1    Foster, R.2    Northfield, T.C.3
  • 15
    • 20344382725 scopus 로고    scopus 로고
    • Technology insight: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease
    • Lundberg JO, Hellström PM, Fagerhol MK, et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:96-102.
    • (2005) Nat Clin Pract Gastroenterol Hepatol. , vol.2 , pp. 96-102
    • Lundberg, J.O.1    Hellström, P.M.2    Fagerhol, M.K.3
  • 16
    • 77955116467 scopus 로고    scopus 로고
    • Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis
    • van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
    • (2010) BMJ , vol.341 , pp. c3369
    • Van Rheenen, P.F.1    Van De-Vijver, E.2    Fidler, V.3
  • 17
    • 33745524590 scopus 로고    scopus 로고
    • Fecal S100A12: A novel noninvasive marker in children with Crohn's disease
    • de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 2006;12: 566-572.
    • (2006) Inflamm Bowel Dis. , vol.12 , pp. 566-572
    • De Jong, N.S.1    Leach, S.T.2    Day, A.S.3
  • 18
    • 72949086178 scopus 로고    scopus 로고
    • A new rapid home test for faecal calprotectin in ulcerative colitis
    • Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010; 31:323-330.
    • (2010) Aliment Pharmacol Ther. , vol.31 , pp. 323-330
    • Elkjaer, M.1    Burisch, J.2    Voxen Hansen, V.3
  • 19
    • 84856713110 scopus 로고    scopus 로고
    • Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome
    • Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6: 207-214.
    • (2012) J Crohns Colitis. , vol.6 , pp. 207-214
    • Sydora, M.J.1    Sydora, B.C.2    Fedorak, R.N.3
  • 20
    • 84925855479 scopus 로고    scopus 로고
    • Comparison of two immunoassays for measurement of faecal calprotectin in detection of Inflammatory Bowel Disease: (pre)-analytical and diagnostic performance characteristics
    • Oyaert M, Trouve C, Baert F, et al. Comparison of two immunoassays for measurement of faecal calprotectin in detection of Inflammatory Bowel Disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2013;11:1-7.
    • (2013) Clin Chem Lab Med. , vol.11 , pp. 1-7
    • Oyaert, M.1    Trouve, C.2    Baert, F.3
  • 21
    • 84882261789 scopus 로고    scopus 로고
    • Faecal calprotectin: Comparative study of the Quantum Blue rapid test and an established ELISA method
    • Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51:825-831.
    • (2013) Clin Chem Lab Med. , vol.51 , pp. 825-831
    • Coorevits, L.1    Baert, F.J.2    Vanpoucke, H.J.3
  • 22
    • 84887609893 scopus 로고    scopus 로고
    • A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease
    • Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis. 2013;7:e641-e651.
    • (2013) J Crohns Colitis. , vol.7 , pp. e641-e651
    • Lobaton, T.1    Lopez-Garcia, A.2    Rodriguez-Moranta, F.3
  • 23
    • 0034828501 scopus 로고    scopus 로고
    • Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm
    • Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96:2683-2687.
    • (2001) Am J Gastroenterol , vol.96 , pp. 2683-2687
    • Husebye, E.1    Ton, H.2    Johne, B.3
  • 24
    • 0029846527 scopus 로고    scopus 로고
    • Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin
    • Gilbert JA, Ahlquist DA, Mahoney DW, et al. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol. 1996;31:1001-1005.
    • (1996) Scand J Gastroenterol , vol.31 , pp. 1001-1005
    • Gilbert, J.A.1    Ahlquist, D.A.2    Mahoney, D.W.3
  • 25
    • 77953693767 scopus 로고    scopus 로고
    • Fecal calprotectin variability in Crohn's disease
    • Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis. 2010;16:1091-1092.
    • (2010) Inflamm Bowel Dis. , vol.16 , pp. 1091-1092
    • Moum, B.1    Jahnsen, J.2    Bernklev, T.3
  • 26
    • 84874105203 scopus 로고    scopus 로고
    • A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease
    • Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37:613-621.
    • (2013) Aliment Pharmacol Ther. , vol.37 , pp. 613-621
    • Naismith, G.D.1    Smith, L.A.2    Barry, S.J.3
  • 27
    • 79955953214 scopus 로고    scopus 로고
    • Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon
    • Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694-700.
    • (2011) Scand J Gastroenterol , vol.46 , pp. 694-700
    • Jensen, M.D.1    Kjeldsen, J.2    Nathan, T.3
  • 28
    • 84859050165 scopus 로고    scopus 로고
    • Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn's disease: A meta-study
    • Bondjemah V, Mary JY, Jones J, et al. Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn's disease: a meta-study. J Crohns Colitis. 2012;6(suppl 1).
    • (2012) J Crohns Colitis. , vol.6
    • Bondjemah, V.1    Mary, J.Y.2    Jones, J.3
  • 30
    • 0033795259 scopus 로고    scopus 로고
    • A simple method for assessing intestinal inflammation in Crohn's disease
    • Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
    • (2000) Gut. , vol.47 , pp. 506-513
    • Tibble, J.1    Teahon, K.2    Thjodleifsson, B.3
  • 31
    • 0033784967 scopus 로고    scopus 로고
    • Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy
    • Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-2837.
    • (2000) Am J Gastroenterol , vol.95 , pp. 2831-2837
    • Limburg, P.J.1    Ahlquist, D.A.2    Sandborn, W.J.3
  • 32
    • 0038359391 scopus 로고    scopus 로고
    • Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children
    • Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49:861-867.
    • (2003) Clin Chem. , vol.49 , pp. 861-867
    • Carroccio, A.1    Iacono, G.2    Cottone, M.3
  • 33
    • 1542394043 scopus 로고    scopus 로고
    • Role of faecal calprotectin as non-invasive marker of intestinal inflammation
    • Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35: 642-647.
    • (2003) Dig Liver Dis. , vol.35 , pp. 642-647
    • Costa, F.1    Mumolo, M.G.2    Bellini, M.3
  • 34
    • 2442607808 scopus 로고    scopus 로고
    • Faecal calprotectin: A new marker for Crohn's disease?
    • Wassell J, Dolwani S, Metzner M, et al. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem. 2004;41:230-232.
    • (2004) Ann Clin Biochem. , vol.41 , pp. 230-232
    • Wassell, J.1    Dolwani, S.2    Metzner, M.3
  • 35
    • 36749059545 scopus 로고    scopus 로고
    • Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation
    • Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374-1378.
    • (2007) Inflamm Bowel Dis. , vol.13 , pp. 1374-1378
    • Chung-Faye, G.1    Hayee, B.2    Maestranzi, S.3
  • 36
    • 36749098918 scopus 로고    scopus 로고
    • Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
    • Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706-1713.
    • (2007) Gut. , vol.56 , pp. 1706-1713
    • Kaiser, T.1    Langhorst, J.2    Wittkowski, H.3
  • 37
    • 33847383306 scopus 로고    scopus 로고
    • Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease
    • D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
    • (2007) Int J Colorectal Dis. , vol.22 , pp. 429-437
    • D'Inca, R.1    Dal Pont, E.2    Di Leo, V.3
  • 38
    • 34548661281 scopus 로고    scopus 로고
    • Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: Combination of parameters does not improve diagnostic accuracy of calprotectin
    • Schröder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther. 2007;26:1035-1042.
    • (2007) Aliment Pharmacol Ther. , vol.26 , pp. 1035-1042
    • Schröder, O.1    Naumann, M.2    Shastri, Y.3
  • 39
    • 35348836239 scopus 로고    scopus 로고
    • Accuracy of four fecal assays in the diagnosis of colitis
    • Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-1706.
    • (2007) Dis Colon Rectum. , vol.50 , pp. 1697-1706
    • Schoepfer, A.M.1    Trummler, M.2    Seeholzer, P.3
  • 40
    • 38849194737 scopus 로고    scopus 로고
    • Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies
    • Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14: 32-39.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 32-39
    • Schoepfer, A.M.1    Trummler, M.2    Seeholzer, P.3
  • 41
    • 37849053698 scopus 로고    scopus 로고
    • Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices
    • Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
    • (2008) Am J Gastroenterol , vol.103 , pp. 162-169
    • Langhorst, J.1    Elsenbruch, S.2    Koelzer, J.3
  • 42
    • 16844377257 scopus 로고    scopus 로고
    • Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms
    • Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455.
    • (2005) J Pediatr Gastroenterol Nutr. , vol.40 , pp. 450-455
    • Fagerberg, U.L.1    Loof, L.2    Myrdal, U.3
  • 43
    • 33947683926 scopus 로고    scopus 로고
    • Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy
    • von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813.
    • (2007) Am J Gastroenterol , vol.102 , pp. 803-813
    • Von Roon, A.C.1    Karamountzos, L.2    Purkayastha, S.3
  • 44
    • 33745714449 scopus 로고    scopus 로고
    • Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease
    • Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720-725.
    • (2006) Scand J Gastroenterol , vol.41 , pp. 720-725
    • Kolho, K.L.1    Raivio, T.2    Lindahl, H.3
  • 45
    • 37349120717 scopus 로고    scopus 로고
    • Fecal calprotectin: A quantitative marker of colonic inflammation in children with inflammatory bowel disease
    • Fagerberg UL, Lööf L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420.
    • (2007) J Pediatr Gastroenterol Nutr. , vol.45 , pp. 414-420
    • Fagerberg, U.L.1    Lööf, L.2    Lindholm, J.3
  • 46
    • 51849157847 scopus 로고    scopus 로고
    • Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome
    • Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275-1280.
    • (2008) Clin Chem Lab Med. , vol.46 , pp. 1275-1280
    • Otten, C.M.1    Kok, L.2    Witteman, B.J.3
  • 47
    • 41149109122 scopus 로고    scopus 로고
    • Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children
    • Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359-366.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 359-366
    • Sidler, M.A.1    Leach, S.T.2    Day, A.S.3
  • 48
    • 66049137260 scopus 로고    scopus 로고
    • Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease
    • Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15: 199-205.
    • (2009) Inflamm Bowel Dis. , vol.15 , pp. 199-205
    • Ashorn, S.1    Honkanen, T.2    Kolho, K.L.3
  • 49
    • 84861882865 scopus 로고    scopus 로고
    • The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease
    • Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2012;107:941-949.
    • (2012) Am J Gastroenterol , vol.107 , pp. 941-949
    • Henderson, P.1    Casey, A.2    Lawrence, S.J.3
  • 50
    • 84882975180 scopus 로고    scopus 로고
    • Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care
    • Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol. 2013;48: 1048-1054.
    • (2013) Scand J Gastroenterol , vol.48 , pp. 1048-1054
    • Pavlidis, P.1    Chedgy, F.J.2    Tibble, J.A.3
  • 51
    • 30344473317 scopus 로고    scopus 로고
    • Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease
    • Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9-15.
    • (2006) J Pediatr Gastroenterol Nutr. , vol.42 , pp. 9-15
    • Canani, R.B.1    De Horatio, L.T.2    Terrin, G.3
  • 52
    • 79954476797 scopus 로고    scopus 로고
    • Fecal calprotectin: A selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy
    • Koulaouzidis A, Douglas S, Rogers MA, et al. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol. 2011;46:561-566.
    • (2011) Scand J Gastroenterol , vol.46 , pp. 561-566
    • Koulaouzidis, A.1    Douglas, S.2    Rogers, M.A.3
  • 53
    • 0034862994 scopus 로고    scopus 로고
    • Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma
    • Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-408.
    • (2001) Gut. , vol.49 , pp. 402-408
    • Tibble, J.1    Sigthorsson, G.2    Foster, R.3
  • 54
    • 4344560517 scopus 로고    scopus 로고
    • Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: Comparison with an immunochemical test for occult blood (FlexSure OBT)
    • Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329-1333.
    • (2004) Gut. , vol.53 , pp. 1329-1333
    • Hoff, G.1    Grotmol, T.2    Thiis-Evensen, E.3
  • 55
    • 1242269322 scopus 로고    scopus 로고
    • Bowel inflammation as measured by fecal calprotectin: A link between lifestyle factors and colorectal cancer risk
    • Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279-284.
    • (2004) Cancer Epidemiol Biomarkers Prev. , vol.13 , pp. 279-284
    • Poullis, A.1    Foster, R.2    Shetty, A.3
  • 56
    • 77951771367 scopus 로고    scopus 로고
    • Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers
    • Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259-263.
    • (2010) Ann Clin Biochem. , vol.47 , pp. 259-263
    • Joshi, S.1    Lewis, S.J.2    Creanor, S.3
  • 57
    • 77149139853 scopus 로고    scopus 로고
    • Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: Correlation with laboratory parameters, clinical, endoscopic and histological indexes
    • Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221.
    • (2009) BMC Res Notes. , vol.2 , pp. 221
    • Vieira, A.1    Fang, C.B.2    Rolim, E.G.3
  • 58
    • 0001607738 scopus 로고
    • Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)
    • Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
    • (1989) Gut. , vol.30 , pp. 983-989
    • Mary, J.Y.1    Modigliani, R.2
  • 59
    • 4744375545 scopus 로고    scopus 로고
    • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD
    • Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
    • (2004) Gastrointest Endosc. , vol.60 , pp. 505-512
    • Daperno, M.1    D'Haens, G.2    Van Assche, G.3
  • 60
    • 78649583974 scopus 로고    scopus 로고
    • Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD
    • Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16:2131-2136.
    • (2010) Inflamm Bowel Dis. , vol.16 , pp. 2131-2136
    • Sipponen, T.1    Nuutinen, H.2    Turunen, U.3
  • 61
    • 73849135965 scopus 로고    scopus 로고
    • Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
    • Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.
    • (2010) Am J Gastroenterol , vol.105 , pp. 162-169
    • Schoepfer, A.M.1    Beglinger, C.2    Straumann, A.3
  • 62
    • 6344246551 scopus 로고    scopus 로고
    • Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease
    • Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
    • (2004) Scand J Gastroenterol , vol.39 , pp. 1017-1020
    • Roseth, A.G.1    Aadland, E.2    Grzyb, K.3
  • 63
    • 0031915148 scopus 로고    scopus 로고
    • Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
    • D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
    • (1998) Gastroenterology , vol.114 , pp. 262-267
    • D'Haens, G.R.1    Geboes, K.2    Peeters, M.3
  • 64
    • 0034906225 scopus 로고    scopus 로고
    • Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease
    • Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
    • (2001) J Pediatr Gastroenterol Nutr. , vol.33 , pp. 14-22
    • Bunn, S.K.1    Bisset, W.M.2    Main, M.J.3
  • 65
    • 54049150524 scopus 로고    scopus 로고
    • Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease
    • Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392-1398.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 1392-1398
    • Sipponen, T.1    Savilahti, E.2    Karkkainen, P.3
  • 66
    • 84876411893 scopus 로고    scopus 로고
    • Mucosal healing in Crohn's disease: A systematic review
    • De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2013;19:429-444.
    • (2013) Inflamm Bowel Dis. , vol.19 , pp. 429-444
    • De Cruz, P.1    Kamm, M.A.2    Prideaux, L.3
  • 67
    • 10744224387 scopus 로고    scopus 로고
    • Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    • Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
    • (2004) Gastroenterology , vol.126 , pp. 402-413
    • Rutgeerts, P.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 68
    • 34147209958 scopus 로고    scopus 로고
    • Mucosal healing in inflammatory bowel disease: Impossible ideal or therapeutic target?
    • Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56: 453-455.
    • (2007) Gut. , vol.56 , pp. 453-455
    • Rutgeerts, P.1    Vermeire, S.2    Van Assche, G.3
  • 69
    • 34547503869 scopus 로고    scopus 로고
    • Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
    • Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
    • (2007) Gastroenterology , vol.133 , pp. 412-422
    • Froslie, K.F.1    Jahnsen, J.2    Moum, B.A.3
  • 70
    • 70450164329 scopus 로고    scopus 로고
    • Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease
    • D'Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009;15:1599-1604.
    • (2009) Inflamm Bowel Dis. , vol.15 , pp. 1599-1604
    • D'Haens, G.R.1    Fedorak, R.2    Lemann, M.3
  • 71
    • 75449114677 scopus 로고    scopus 로고
    • Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    • quiz e10-e11
    • Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468; quiz e10-e11.
    • (2010) Gastroenterology , vol.138 , pp. 463-468
    • Baert, F.1    Moortgat, L.2    Van Assche, G.3
  • 72
    • 0036161216 scopus 로고    scopus 로고
    • A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    • Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
    • (2002) Gastroenterology , vol.122 , pp. 512-530
    • Sandborn, W.J.1    Feagan, B.G.2    Hanauer, S.B.3
  • 73
    • 84862777782 scopus 로고    scopus 로고
    • Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial
    • e2
    • Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-1111. e2.
    • (2012) Gastroenterology , vol.142 , pp. 1102-1111
    • Rutgeerts, P.1    Van Assche, G.2    Sandborn, W.J.3
  • 74
    • 53249097726 scopus 로고    scopus 로고
    • Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial
    • D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123-1129.
    • (2008) Gastroenterology , vol.135 , pp. 1123-1129
    • D'Haens, G.R.1    Vermeire, S.2    Van Assche, G.3
  • 75
    • 39449085441 scopus 로고    scopus 로고
    • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial
    • D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
    • (2008) Lancet , vol.371 , pp. 660-667
    • D'Haens, G.1    Baert, F.2    Van Assche, G.3
  • 76
    • 0025322362 scopus 로고
    • Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not of endoscopically viewed inflammation
    • Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut. 1990;31:325-328.
    • (1990) Gut. , vol.31 , pp. 325-328
    • Olaison, G.1    Sjodahl, R.2    Tagesson, C.3
  • 77
    • 77149154328 scopus 로고    scopus 로고
    • Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment
    • Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol. 2010;45:325-331.
    • (2010) Scand J Gastroenterol , vol.45 , pp. 325-331
    • Sipponen, T.1    Bjorkesten, C.G.2    Farkkila, M.3
  • 78
    • 0025796809 scopus 로고
    • Development and validation of a pediatric Crohn's disease activity index
    • Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
    • (1991) J Pediatr Gastroenterol Nutr. , vol.12 , pp. 439-447
    • Hyams, J.S.1    Ferry, G.D.2    Mandel, F.S.3
  • 79
    • 3543036981 scopus 로고    scopus 로고
    • Fecal lactoferrin: A new parameter to monitor infliximab therapy
    • Buderus S, Boone J, Lyerly D, et al. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039.
    • (2004) Dig Dis Sci. , vol.49 , pp. 1036-1039
    • Buderus, S.1    Boone, J.2    Lyerly, D.3
  • 80
    • 83755194964 scopus 로고    scopus 로고
    • Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels
    • Hamalainen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17:5166-5171.
    • (2011) World J Gastroenterol , vol.17 , pp. 5166-5171
    • Hamalainen, A.1    Sipponen, T.2    Kolho, K.L.3
  • 81
    • 84859604934 scopus 로고    scopus 로고
    • Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease
    • af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528-537.
    • (2012) Scand J Gastroenterol , vol.47 , pp. 528-537
    • Af Bjorkesten, C.G.1    Nieminen, U.2    Turunen, U.3
  • 82
    • 84866548953 scopus 로고    scopus 로고
    • Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF alpha blocking agents
    • Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF alpha blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
    • (2012) Inflamm Bowel Dis. , vol.18 , pp. 2011-2017
    • Molander, P.1    Af Bjorkesten, C.G.2    Mustonen, H.3
  • 83
    • 79960560410 scopus 로고    scopus 로고
    • Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: A prospective study
    • Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462-469.
    • (2011) Aliment Pharmacol Ther. , vol.34 , pp. 462-469
    • Laharie, D.1    Mesli, S.2    El Hajbi, F.3
  • 84
    • 0034234796 scopus 로고    scopus 로고
    • Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
    • Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
    • (2000) Gastroenterology , vol.119 , pp. 15-22
    • Tibble, J.A.1    Sigthorsson, G.2    Bridger, S.3
  • 85
    • 76649144480 scopus 로고    scopus 로고
    • Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: A prospective study
    • Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
    • (2010) Eur J Gastroenterol Hepatol. , vol.22 , pp. 340-345
    • Kallel, L.1    Ayadi, I.2    Matri, S.3
  • 86
    • 70349484242 scopus 로고    scopus 로고
    • Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
    • Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
    • (2009) Inflamm Bowel Dis. , vol.15 , pp. 1190-1198
    • Gisbert, J.P.1    Bermejo, F.2    Perez-Calle, J.L.3
  • 87
    • 49349114912 scopus 로고    scopus 로고
    • Can calprotectin predict relapse risk in inflammatory bowel disease?
    • D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103: 2007-2014.
    • (2008) Am J Gastroenterol , vol.103 , pp. 2007-2014
    • D'Inca, R.1    Dal Pont, E.2    Di Leo, V.3
  • 88
    • 44349168884 scopus 로고    scopus 로고
    • Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease
    • Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 669-673
    • Walkiewicz, D.1    Werlin, S.L.2    Fish, D.3
  • 89
    • 77955701075 scopus 로고    scopus 로고
    • Faecal calprotectin in children with clinically quiescent inflammatory bowel disease
    • Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45: 872-877.
    • (2010) Scand J Gastroenterol , vol.45 , pp. 872-877
    • Sipponen, T.1    Kolho, K.L.2
  • 90
    • 0008690916 scopus 로고
    • Cortisone in ulcerative colitis: Final report on a therapeutic trial
    • Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041-1048.
    • (1955) Br Med J. , vol.2 , pp. 1041-1048
    • Truelove, S.C.1    Witts, L.J.2
  • 91
    • 83955162272 scopus 로고    scopus 로고
    • Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped
    • quiz e31
    • Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70; quiz e31.
    • (2012) Gastroenterology , vol.142 , pp. 63-70
    • Louis, E.1    Mary, J.Y.2    Vernier-Massouille, G.3
  • 92
    • 84866771901 scopus 로고    scopus 로고
    • Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A sub-analysis of the STORI study
    • de Suray N, Salleron J, Vernier-Massouille G, et al. Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A sub-analysis of the STORI study. Gastroenterology. 2012;142:S-149.
    • (2012) Gastroenterology , vol.142 , pp. S-149
    • De Suray, N.1    Salleron, J.2    Vernier-Massouille, G.3
  • 93
    • 14544308315 scopus 로고    scopus 로고
    • Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
    • Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
    • (2005) Gut. , vol.54 , pp. 364-368
    • Costa, F.1    Mumolo, M.G.2    Ceccarelli, L.3
  • 94
    • 84861869143 scopus 로고    scopus 로고
    • Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
    • Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
    • (2012) Inflamm Bowel Dis. , vol.18 , pp. 1894-1899
    • Mao, R.1    Xiao, Y.L.2    Gao, X.3
  • 95
    • 84886287272 scopus 로고    scopus 로고
    • Elevated faecal calprotectin predicts disease progression in Crohn's disease
    • Kennedy NA, Chang J, Guy M, et al. Elevated faecal calprotectin predicts disease progression in Crohn's disease. Gastroenterology. 2013;144:S-105.
    • (2013) Gastroenterology , vol.144 , pp. S-105
    • Kennedy, N.A.1    Chang, J.2    Guy, M.3
  • 96
    • 33144463875 scopus 로고    scopus 로고
    • European evidence based consensus on the diagnosis and management of Crohn's disease: Special situations
    • Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(suppl 1):i36-i58.
    • (2006) Gut. , vol.55 , pp. i36-i58
    • Caprilli, R.1    Gassull, M.A.2    Escher, J.C.3
  • 97
    • 0023720136 scopus 로고
    • Endoscopic lesions in Crohn's disease early after ileocecal resection
    • Tytgat GN, Mulder CJ, Brummelkamp WH. Endoscopic lesions in Crohn's disease early after ileocecal resection. Endoscopy. 1988;20: 260-262.
    • (1988) Endoscopy. , vol.20 , pp. 260-262
    • Tytgat, G.N.1    Mulder, C.J.2    Brummelkamp, W.H.3
  • 98
    • 0025013473 scopus 로고
    • Predictability of the postoperative course of Crohn's disease
    • Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99: 956-963.
    • (1990) Gastroenterology , vol.99 , pp. 956-963
    • Rutgeerts, P.1    Geboes, K.2    Vantrappen, G.3
  • 99
    • 0021266269 scopus 로고
    • Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery
    • Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
    • (1984) Gut. , vol.25 , pp. 665-672
    • Rutgeerts, P.1    Geboes, K.2    Vantrappen, G.3
  • 100
    • 84884243191 scopus 로고    scopus 로고
    • Optimising post-operative Crohn's disease management: Best drug therapy alone versus colonoscopic monitoring with treatment step-up: POCER study
    • De Cruz P, Kamm MA, Hamilton AL, et al. Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up: POCER study. Gastroenterology. 2013;144:S-164.
    • (2013) Gastroenterology , vol.144 , pp. S-164
    • De Cruz, P.1    Kamm, M.A.2    Hamilton, A.L.3
  • 101
    • 45849151071 scopus 로고    scopus 로고
    • Non-invasive techniques for assessing postoperative recurrence in Crohn's disease
    • Biancone L, Onali S, Calabrese E, et al. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig Liver Dis. 2008;40(suppl 2):S265-S270.
    • (2008) Dig Liver Dis. , vol.40 , pp. S265-S270
    • Biancone, L.1    Onali, S.2    Calabrese, E.3
  • 102
    • 33644529742 scopus 로고    scopus 로고
    • The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: A comparison with ultrasound
    • Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10:17-22.
    • (2006) Eur Rev Med Pharmacol Sci. , vol.10 , pp. 17-22
    • Orlando, A.1    Modesto, I.2    Castiglione, F.3
  • 103
    • 34249900168 scopus 로고    scopus 로고
    • Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease
    • Scarpa M, D'Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum. 2007; 50:861-869.
    • (2007) Dis Colon Rectum. , vol.50 , pp. 861-869
    • Scarpa, M.1    D'Inca, R.2    Basso, D.3
  • 104
    • 66749185327 scopus 로고    scopus 로고
    • Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease
    • Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674.
    • (2009) Br J Surg. , vol.96 , pp. 663-674
    • Lamb, C.A.1    Mohiuddin, M.K.2    Gicquel, J.3
  • 105
    • 84863627837 scopus 로고    scopus 로고
    • Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: Partial benefit by infliximab-A pilot study
    • Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab-a pilot study. Dig Dis Sci. 2012;57: 1341-1348.
    • (2012) Dig Dis Sci. , vol.57 , pp. 1341-1348
    • Sorrentino, D.1    Terrosu, G.2    Paviotti, A.3
  • 106
    • 84925844183 scopus 로고    scopus 로고
    • Faecal calprotectin cannot predict endoscopic disease recurrence one year after ileocaecal resection for Crohn's disease
    • Lasson A, Strid H, Isaksson S, et al. Faecal calprotectin cannot predict endoscopic disease recurrence one year after ileocaecal resection for Crohn's disease. Gastroenterology. 2013;144:S-762.
    • (2013) Gastroenterology , vol.144 , pp. S-762
    • Lasson, A.1    Strid, H.2    Isaksson, S.3
  • 107
    • 84925855828 scopus 로고    scopus 로고
    • Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease
    • Primas C, Fruhwald G, Angelberger S, et al. Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease. Gastroenterology. 2013;144:S-619-S-620.
    • (2013) Gastroenterology , vol.144 , pp. S619-S620
    • Primas, C.1    Fruhwald, G.2    Angelberger, S.3
  • 108
    • 84887610600 scopus 로고    scopus 로고
    • Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease?
    • Yamamoto T, Kotze PG. Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease? J Crohns Colitis. 2013;7:e712.
    • (2013) J Crohns Colitis. , vol.7 , pp. e712
    • Yamamoto, T.1    Kotze, P.G.2
  • 109
    • 84925841287 scopus 로고    scopus 로고
    • Accuracy of faecal calprotectin in the assessment of post-operative endoscopic recurrence in patients with Crohn's disease
    • Boschetti G, Phelip G, Moussata D, et al. Accuracy of faecal calprotectin in the assessment of post-operative endoscopic recurrence in patients with Crohn's disease. United Eur Gastroenterol J. 2013;1:526.
    • (2013) United Eur Gastroenterol J. , vol.1 , pp. 526
    • Boschetti, G.1    Phelip, G.2    Moussata, D.3
  • 110
    • 84904367379 scopus 로고    scopus 로고
    • Faecal calprotectin helps determine the need for post-operative colonoscopy in Crohn's disease. Prospective longitudinal endoscopic validation results from the POCER study
    • Wright E, De Cruz P, Kamm M, et al. Faecal calprotectin helps determine the need for post-operative colonoscopy in Crohn's disease. Prospective longitudinal endoscopic validation results from the POCER study. United Eur Gastroenterol J. 2013;1:A35.
    • (2013) United Eur Gastroenterol J. , vol.1 , pp. A35
    • Wright, E.1    De Cruz, P.2    Kamm, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.